First Trust NASDAQ Cybersecurity ETF vs State Street SPDR S&P Biotech ETF — how do they compare? First Trust NASDAQ Cybersecurity ETF trades at $100.41, while State Street SPDR S&P Biotech ETF trades at $159.2. Which is the better fit depends on your goals.
| CIBR | XBI | |
|---|---|---|
52-Week High | $100.60 | $164.28 |
52-Week Low | $60.74 | $86.92 |
Sector | — | Broad Market / Factor |
Signals from Pluang's Aura AI — not financial advice
CIBR trades at $100.86, up 0.26% today, with strong bullish momentum from moving averages but overbought RSI signals. The cybersecurity ETF has outperformed the S&P 500 by 3:1 year-to-date, benefiting from AI-driven security spending growth exceeding $300 billion in 2026. Recent institutional activity shows mixed sentiment with Bank of America reducing its stake while First Trust Advisors increased its position by 12.4%.
Outlook remains positive given cybersecurity's essential role in AI expansion, though high RSI levels suggest near-term consolidation risk. The sector's defensive growth characteristics and increasing attack surfaces provide long-term tailwinds, but concentrated tech exposure and valuation concerns warrant monitoring.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Trailing returns across standard periods
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index includes securities of companies classified as cyber security companies. The fund is non-diversified.
Read more on CIBR →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →